Cagrilintide ge 'nar análogo ar amilina ntsoni xi maa nzaki. Amylin ge 'nar hormona peptídica co-secretada ya células ar β pancreáticos junto ar insulina; regulando ar equilibrio energético a través de saciedad, vaciado gástrico retardado, ne inhibición glucagón.
amilina da ocurre naturalmente, , agrega hingi hembi da ne posee pobre nzäm'bu, limitando ár nt'ot'e clínica. análogos derivados ar amilina temprana komo pramlintide requirió inyecciones frecuentes nu'bya farmacocinética subóptima pa efectos terapéuticos jar klase 2 diabetes.
Cagrilintide logra nuna nt'ot'e prolongada a través de nyokwi ar cadena ar ácidos grasos – dosificación 'nar pa semanal ge ar punto final buscado. ensayos clínicos xi demostrado potentes efectos suprimiendo ar apetito, 'nar nt'ot'e mbo complementario ar demuestra jar comparación ko ar semaglutida.
'nar combinación nthe fija (CagriSema) xi xi desarrollado . Experimental weight-loss data indicates the combination exceeds either agent alone in efficacy.
The continued advancement of cagrilintide expands the previously defined therapeutic potential of amylin mimetics; multi-target synergistic treatment of metabolic disorders is the clear future direction.
Secuencia
{Eicosanedioic acid-γ-Glu}-Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Glu-Phe-Leu-Arg-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Pro-NH2 (puente ar disulfuro:Cys3-Cys8)
'bede ya CAS
1415456-99-3
Fórmula molecular
C194H312N54O59S2
Be̲xu molecular
4409.01 g yá mol
Cagrilintide Related Research
1.Appetite Suppression and Satiety Enhancement
As an amylin analog, rapid crossing of the blood brain barrier is key to Cagrilintide’s effect.
Direct targeting of specific brain regions regulating pure ‘hunger’ is what sets it apart – activation of the calcitonin receptor (energy sufficiency signaling) reduces, if not eliminates, food cravings centrally.
Willpower based dieting cannot replicate this physiological change to an individual’s set point.
2.Delays in gastric emptying and all subsequent digestion
Inhibition of gastric smooth muscle contractions and partial relaxation of the pylorus provides a more physical form of sustained fullness.
Nutrient absorption is reduced, postprandial blood glucose (and to a large extent all metabolic parameters) are kept as stable as possible.
3.Inhibits postprandial glucagon secretion
Glucagon is a hormone that promotes hepatic glycogenolysis ne gluconeogenesis; effectively serving as a hyperglycemic agent.
Cagrilintide mimics the very specific postprandial secretion that alpha cells gi, signaling through the brain’s nervous system that this release has occurred.
Significant reduction in said secretion is the end result – lowering postprandial blood glucose being one of the primary benefits.
Improving dietary patterns for type 2 diabetes patients is closely tied to this process; consuming various forms of ‘energy’ can be approached with near-complete confidence without constant glucose monitoring.
4.Synergistic Action with GLP-1 Receptor Agonists
Highly complementary mechanisms are exhibited between cagrilintide and these agonists.
GLP-1 itself focuses more on satiety, while amylin analogues (to a near perfect extent) suppress all forms of hunger.
A dual mechanism, multi-targeted pathophysiology based approach to obesity and diabetes is what the combination offers.
Studies (CagriSema being the most recent) have shown superior weight loss and improved glycemic control when both are used together.
COA
HPLC
MS
